Stacie McKnight, DO
Family Medicine · Mc Kees Rocks, PANPI 1952509374
Payments from drug & device makers
Across 229 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$729
- GSK$444
- Novo Nordisk$431
- AstraZeneca$352
- Pfizer$240
- Lilly USA, LLC$229
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,197100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $729 |
| GSK | 29 | $444 |
| Novo Nordisk | 22 | $431 |
| AstraZeneca | 23 | $352 |
| Pfizer | 13 | $240 |
| Lilly USA, LLC | 14 | $229 |
| Boehringer Ingelheim | 13 | $182 |
| Merck | 10 | $164 |
| Amgen | 9 | $148 |
| Johnson & Johnson | 6 | $134 |
| Edwards Lifesciences | 2 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $80 |
| Abiomed | 2 | $69 |
| Phathom Pharmaceuticals, Inc. | 2 | $66 |
| Novartis | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Eisai Inc. | 3 | $60 |
| Biohaven Pharmaceuticals, Inc. | 4 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Amarin Pharma, Inc. | 3 | $55 |
| UCB, Inc. | 1 | $48 |
| Astellas Pharma US Inc | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Sanofi Pasteur Inc. | 1 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Gilead | 2 | $33 |
| Strongbridge US Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Stryker | 1 | $20 |
| Vyera Pharmaceuticals, LLC | 1 | $17 |
| Abbott | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Nevro Corp. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$4,197 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 143 | $89,894 |
| OzempicSemaglutide | 74 | $74,394 |
| JardianceEmpagliflozin | 68 | $61,110 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $58,688 |
| PrezcobixDarunavir/Cobicistat | 29 | $38,772 |
| XareltoRivaroxaban | 40 | $20,419 |
| UbrelvyUbrogepant | 19 | $20,296 |
| JanuviaSitagliptin Phosphate | 17 | $19,416 |
| TradjentaLinagliptin | 26 | $12,564 |
| LinzessLinaclotide | 15 | $12,535 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $12,073 |
| QuviviqDaridorexant Hcl | 25 | $11,562 |
| MounjaroTirzepatide | 11 | $11,520 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $10,302 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $240 | $95,529162 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $182 | $80,609108 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $444 | $77,459121 claims |
| Novo NordiskOzempic | $431 | $74,39474 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $134 | $59,19269 claims |
| AbbVieUbrelvy, Linzess | $729 | $32,83134 claims |
| MerckJanuvia, Dulera | $164 | $23,33228 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $23 | $11,56225 claims |
| Lilly USA, LLCMounjaro | $229 | $11,52011 claims |
| AstraZenecaBreztri Aerosphere | $352 | $10,30215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $61 | $3,65614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Mc Kees Rocks
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.